Mirum Pharmaceuticals to acquire Bluejay Therapeutics for $820m.

Mirum Pharmaceuticals, a rare disease company, agreed to acquire Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases, for $820m. “This acquisition fits squarely with what we do best - advancing high-impact medicines for patients with rare diseases through disciplined development, regulatory innovation, and commercial excellence. Brelovitug in HDV leverages our deep expertise in rare liver disease and builds on the relationships we’ve established with key providers through the volixibat and LIVMARLI programs. The Bluejay team has done commendable work advancing brelovitug to this stage and we look forward to building on that progress to bring this important new treatment to people living with HDV," Chris Peetz, Mirum Pharmaceuticals Chief Executive Officer.